NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics<
22 Jun 2023

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics

Proceeds will be used to advance the lead program, a click-cleavable ADC targeting TAG72, into the clinic, and expand the pipeline
Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer<
20 Jun 2023

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer

Strengthening of strategic option license agreement to cover additional novel ADC targets
SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program<
20 Jun 2023

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

Dr. Favre brings extensive experience in gene therapy, immunology and drug development
CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment<
20 Jun 2023

CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment

Investment to fund its first industrial deployment and entry into clinical trials.
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway<
14 Jun 2023

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

LAVA-1207 for the treatment of prostate cancer will continue as the lead program
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results<
09 Jun 2023

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVA
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development<
01 Jun 2023

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

LAVA is also eligible to receive potential development, regulatory and commercialization milestone payments and tiered royalties.
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy<
31 May 2023

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market
Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference<
31 May 2023

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

Adam Levy will be giving a presentation at the Jefferies Healthcare Conference at 9:30 a.m. ET June 9th 2023
Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline<
30 May 2023

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

Strengthening of strategic option license agreement to cover additional novel ADC targets

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.